Sridhar Nonavinkere Srivatsan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sridhar Nonavinkere Srivatsan has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Matthew J. Walter
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
28 shared publications - Julie M. Bailis
Oncology Research, Amgen Inc, Thousand Oaks, California
23 shared publications - Zhongsheng You
Department of Cell Biology and Physiology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA
23 shared publications - Claudia Cabrera Pastrana
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA
22 shared publications - Michael O. Alberti
Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, USA
22 shared publications - Timothy A. Graubert
Massachusetts General Hospital 4 , Cancer Center, Harvard Medical School, Boston, Massachusetts
22 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Leukemia
- p. 1-11
Sensitivity to ATR–CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss
SRSF2 mutations occur in 5–15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML patients and controls showed that SRSF2 -mutant cells are sensitive to CHK1 and WEE1 inhibitors. To test causality, we engineered isogenic K562 cell line clones expressing SRSF2 P95H/L/R mutations. RNA sequencing confirmed splicing aberrations characteristic of MDS/AML in these clones. We found that SRSF2 P95H/L/R sensitizes cells to ATR–CHK1–WEE1 inhibition. Bone marrow progenitors from Srsf2 P95H knock-in mice showed heightened sensitivity to CHK1 inhibition, corroborating the human SRSF2 -mutant data. U2af1 S34F knock-in mouse progenitors extended this vulnerability to another spliceosome-mutant context. In contrast, RUNX1 mutations were linked to resistance to CHK1 and WEE1 inhibition in SRSF2 -mutant AML samples. Runx1 disruption also caused resistance to CHK1 inhibitors in knock-in mouse progenitors harboring Srsf2 P95H or U2af1 S34F , indicating that RUNX1 loss of function is a mechanism of resistance. In conclusion, SRSF2 and U2AF1 mutations are biomarkers of sensitivity to ATR–CHK1 pathway inhibitors, while RUNX1 mutations cause resistance in splicing factor-mutant cells. These biomarkers can support patient stratification in MDS/AML.
- 6 October 2026
- Published by Springer Nature in Leukemia
- p. 1-11
Open AccessSensitivity to ATR–CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss
SRSF2 mutations occur in 5–15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML patients and controls showed that SRSF2 -mutant cells are sensitive to CHK1 and WEE1 inhibitors. To test causality, we engineered isogenic K562 cell line clones expressing SRSF2 P95H/L/R mutations. RNA sequencing confirmed splicing aberrations characteristic of MDS/AML in these clones. We found that SRSF2 P95H/L/R sensitizes cells to ATR–CHK1–WEE1 inhibition. Bone marrow progenitors from Srsf2 P95H knock-in mice showed heightened sensitivity to CHK1 inhibition, corroborating the human SRSF2 -mutant data. U2af1 S34F knock-in mouse progenitors extended this vulnerability to another spliceosome-mutant context. In contrast, RUNX1 mutations were linked to resistance to CHK1 and WEE1 inhibition in SRSF2 -mutant AML samples. Runx1 disruption also caused resistance to CHK1 inhibitors in knock-in mouse progenitors harboring Srsf2 P95H or U2af1 S34F , indicating that RUNX1 loss of function is a mechanism of resistance. In conclusion, SRSF2 and U2AF1 mutations are biomarkers of sensitivity to ATR–CHK1 pathway inhibitors, while RUNX1 mutations cause resistance in splicing factor-mutant cells. These biomarkers can support patient stratification in MDS/AML.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 12 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
GO (BP, CC, MF) enrichment analysis of NMD predicted transcripts (SE) (K562, S34F/SMG1i vs WT/DMSO).
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 12 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
GO (BP, CC, MF) enrichment analysis of NMD predicted transcripts (SE) (K562, S34F/SMG1i vs WT/DMSO).
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
RNA sequencing results for mouse leukemia cells treated with SMG1i and non-transform mouse cells expressing U2AF1 (S34F) sensitivity to SMG1i and rescue experiments.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
RNA sequencing results for mouse leukemia cells treated with SMG1i and non-transform mouse cells expressing U2AF1 (S34F) sensitivity to SMG1i and rescue experiments.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
Differentially spliced junctions (mouse, S34F-/Veh, S34F+/Veh, S34F-/SMG1i, S34F+/SMG1i).
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
Differentially spliced junctions (mouse, S34F-/Veh, S34F+/Veh, S34F-/SMG1i, S34F+/SMG1i).
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
Mutant spliceosome proteins (e.g., U2AF1S34F, SF3B1K700E, or SRSF2P95H) alter RNA splicing in myeloid neoplasms, leading to increased production of nonsense transcripts. Inhibiting the nonsense-mediated RNA decay (NMD) pathway, which is responsible for the degradation of nonsense transcripts, preferentially kills cells expressing mutant spliceosome proteins in vitro. In this study, we used an inhibitor of the kinase SMG1, a key regulator of NMD, to provide in vivo evidence that NMD is a therapeutic vulnerability for splicing factor mutant myeloid neoplasms. Primary mouse acute myeloid leukemia cells and human K562 leukemia cell lines expressing splicing factor mutants were more sensitive than wild-type (WT) cells to in vivo inhibition of SMG1 (SMG1i). Disruption of NMD activity by SMG1i led to increased R-loop levels in spliceosome WT cells, which were further increased in treated U2AF1S34F cells. This R-loop accumulation was accompanied by an increase in DNA damage. Degradation of R-loops with RNase H1 rescued spliceosome mutant cells from NMD inhibition–induced cell death. In U2AF1S34F cells, SMG1i increased NMD transcript isoforms (with reduced but detectable protein levels), which were enriched for DNA repair genes, including ATR and RAD51. Consequently, SMG1i-induced cell death in splicing factor mutant leukemias could be further enhanced by the inhibition of ATR or RAD51. This study shows that in vivo targeting of NMD is a therapeutic strategy to treat myeloid neoplasms with aberrant splicing.Significance:Cells with spliceosome mutations are sensitive to SMG1 inhibition in vivo due to R-loop accumulation, suggesting that nonsense-mediated decay targeting, alone or with DNA repair inhibitors, could be effective in splicing-mutant myeloid neoplasms.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
Mutant spliceosome proteins (e.g., U2AF1S34F, SF3B1K700E, or SRSF2P95H) alter RNA splicing in myeloid neoplasms, leading to increased production of nonsense transcripts. Inhibiting the nonsense-mediated RNA decay (NMD) pathway, which is responsible for the degradation of nonsense transcripts, preferentially kills cells expressing mutant spliceosome proteins in vitro. In this study, we used an inhibitor of the kinase SMG1, a key regulator of NMD, to provide in vivo evidence that NMD is a therapeutic vulnerability for splicing factor mutant myeloid neoplasms. Primary mouse acute myeloid leukemia cells and human K562 leukemia cell lines expressing splicing factor mutants were more sensitive than wild-type (WT) cells to in vivo inhibition of SMG1 (SMG1i). Disruption of NMD activity by SMG1i led to increased R-loop levels in spliceosome WT cells, which were further increased in treated U2AF1S34F cells. This R-loop accumulation was accompanied by an increase in DNA damage. Degradation of R-loops with RNase H1 rescued spliceosome mutant cells from NMD inhibition–induced cell death. In U2AF1S34F cells, SMG1i increased NMD transcript isoforms (with reduced but detectable protein levels), which were enriched for DNA repair genes, including ATR and RAD51. Consequently, SMG1i-induced cell death in splicing factor mutant leukemias could be further enhanced by the inhibition of ATR or RAD51. This study shows that in vivo targeting of NMD is a therapeutic strategy to treat myeloid neoplasms with aberrant splicing.Significance:Cells with spliceosome mutations are sensitive to SMG1 inhibition in vivo due to R-loop accumulation, suggesting that nonsense-mediated decay targeting, alone or with DNA repair inhibitors, could be effective in splicing-mutant myeloid neoplasms.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
GO (BP, CC, MF) enrichment analysis of NMD predicted transcripts (SE) (mouse, S34F+/SMG1 vs S34F-/Vehicle).
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
GO (BP, CC, MF) enrichment analysis of NMD predicted transcripts (SE) (mouse, S34F+/SMG1 vs S34F-/Vehicle).
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
GO BP enrichment analysis of differentially spliced genes (mouse, S34F+/SMG1 vs S34F-/Vehicle, S34F+/SMG1 vs S34F+/Vehicle, S34F+/SMG1 vs S34F-/SMG1i).
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
GO BP enrichment analysis of differentially spliced genes (mouse, S34F+/SMG1 vs S34F-/Vehicle, S34F+/SMG1 vs S34F+/Vehicle, S34F+/SMG1 vs S34F-/SMG1i).
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
Differential gene expression data (mouse, S34F-/SMG1i vs S34F-/Vehicle, S34F+/SMG1i vs S34F-/Vehicle, S34F+/SMG1i vs S34F+/Vehicle, S34F+/SMG1i vs S34F-/SMG1i).
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
Differential gene expression data (mouse, S34F-/SMG1i vs S34F-/Vehicle, S34F+/SMG1i vs S34F-/Vehicle, S34F+/SMG1i vs S34F+/Vehicle, S34F+/SMG1i vs S34F-/SMG1i).
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
RNA sequencing results for K562 cells treated with SMG1i, target validation and rescue experiments.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
RNA sequencing results for K562 cells treated with SMG1i, target validation and rescue experiments.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
SMG1i structure and mouse splicing factor mutant cells sensitivity to SMG1i ex vivo.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage
SMG1i structure and mouse splicing factor mutant cells sensitivity to SMG1i ex vivo.